Searched for
ODOMZO
Sun Pharma sees steady FY27 growth, progresses $11.75 bn Organon integration dealSun Pharma anticipates strong growth in the coming years. The company expects a high single-digit increase in its overall sales by FY2027. ...- Sun Pharma's US innovative drug sales surpass generics for first timeSun Pharma is open to expanding its US manufacturing capabilities in response to the Trump administration's 100% tariff on medicines. The c...
- Sun Pharma says working towards full regulatory resolution at 3 plants facing USFDA actionSun Pharma focuses on compliance across its manufacturing units. It aims for full regulatory resolution at facilities facing USFDA action. ...
- Sun Pharma shares in focus ahead of Q2 results todaySun Pharma Share Price: Sun Pharma is set to announce its Q2 FY25 results, with revenue growth expected to be driven by domestic business a...
- Sun Pharma, Philogen join hands to commercialise skin cancer drug in Europe, Australia, New ZealandSun Pharmaceutical Industries on Tuesday said it has entered into a licensing pact with Philogen SpA to commercialise under-development ski...
- Sun Pharma Q3 Preview: Sales likely to rise but profit may fall YoYAccording to an ETNow poll, the drugmaker’s consolidated revenue for the quarter ended December is seen rising 12.5% on-year to Rs 11,100 c...
- Buy Sun Pharmaceutical Industries, target price Rs 1130: JM FinancialSun Pharmaceutical Industries Ltd., incorporated in the year 1993, is a Large Cap company (having a market cap of Rs 213972.69 Crore) opera...
- Does Sun Pharma's specialty portfolio hold key to its performance?According to the FY 2022 annual report of Sun Pharma, it is ranked number 1 in terms of prescriptions with an 8.34% market share in India. ...
- Buy Sun Pharmaceutical Industries, target Rs 520: CLSASun Pharma is a largecap company, operating in pharmaceuticals and health care sector.
- Sun Pharma rises with R&D and bets on specialty drugsSun Pharma- India's largest drug maker - is vying for its share in the US$9 billion market through a drug, Ilumya, that treats moderate-to-...
- Beyond Sun's pain is a promise of specialty segment: AnalystsSome analysts suggested that investors willing to overlook the subdued outlook.
- Sun Pharma hits 44-month low, down 24% in 7 sessions; what experts sayThe stock fell 12.84 per cent to hit a 44-month low of Rs 495.55 amid weak fourth quarter results.
- Lupin, Cipla, other top drugmakers in fray for Novartis’ brandsThe Novartis portfolio includes top-selling brand TOBI Podhaler, a drug prescribed for symptomatic relief to patients suffering from cystic...
- Sun Pharma Q3 net profit slips 4.7% YoY to Rs 1,471.82 croreSales for the quarter came in at Rs 7,683.24 crore, compared with Rs 7,087.07 crore in the same quarter last year.
- How top Indian drug makers like Sun Pharma, Glenmark are building a brands business in the USWhile the market opportunities to sell brands appear optimistic, that road is less treaded by Indian companies and obvious challenges can l...
- Buy Sun Pharma, with a target of Rs 750: Bank of America Merrill LynchBofA-ML maintains buy rating on Sun Pharma but slashed its 12-month target price to Rs 750 from Rs 790 earlier.
- HSBC says Odomzo deal to strengthen Sun Pharma's specialty business focusThe brokerage has maintained a ‘buy’ rating on the stock with a target price of Rs 797. The target price implies an upside of 27.8% from cu...
- Sun Pharma to acquire oncology product from Novartis for $175 mnThe agreement has been signed between subsidiaries of both the companies and will close following anti-trust clearance and further closing ...
- Sun Pharma rallies on acquisition plans to buy Odomzo drug from NovartisAt 09:45 am, shares of Sun Pharma were trading 1.3 per cent higher at Rs 622. They hit a low of Rs 614 and a high of Rs 624 in the first 30...
- Sun Pharma to buy Novartis' cancer drug OdomzoSun Pharmaceutical today said it has acquired branded oncology product Odomzo from Novartis for an upfront payment of $ 175 million.
Load More
